GWM
RCUS icon

Gilpin Wealth Management’s Arcus Biosciences RCUS Stock Holding History

Gilpin Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$362 Hold
14
– – ﹤0.01% 947
2026
Q2 		$432 Hold
14
– – ﹤0.01% 726
2026
Q1 		$303 Buy
14
+3
+27% +$65 ﹤0.01% 763
2025
Q4 		$263 Buy
+11
New +$224 ﹤0.01% 579

Other funds holding RCUS

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's RCUS Position: Q3 2026 in Review

Gilpin Wealth Management held its Arcus Biosciences (RCUS) position steady in Q3 2026 at 14 shares worth $362. The position accounts for ﹤0.01% of the portfolio, ranked #947.

Gilpin Wealth Management first reported a position in RCUS in Q4 2025 and has held it in 4 quarters since. The position peaked at $432 in Q2 2026. 7 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Gilpin Wealth Management held 14 shares of Arcus Biosciences worth $362 as of Q3 2026.
  • Gilpin Wealth Management left its Arcus Biosciences share count unchanged in Q3 2026.
  • Arcus Biosciences made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #947 holding.
  • Gilpin Wealth Management first reported a position in Arcus Biosciences in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Arcus Biosciences position peaked at $432 in Q2 2026.
  • 7 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.